ÊïéíùíéêÝò ðáñï÷Ýò

ÌÝôñá & ÐñïãñÜììáôá Êïéíùíéêþí Ðáñï÷þí & Åíéó÷ýóåùí

  1. ÂéâëéÜñéï õãåßáò áðüñùí
  2. Éáôñï-öáñìáêåõôéêÞ êÜëõøç
  3. Åðéäüìáôá ãéá Üôïìá ìå HIV/AIDS
  4. ÊÜñôá Ìåôáêßíçóçò Áôüìùí ìå Áíáðçñßåò
  5. Äåëôßï Êïéíùíéêïý Ôïõñéóìïý
  6. ÊÜñôá Ðïëéôéóìïý
  7. Åõêáéñßåò áðáó÷üëçóçò
  8. ÖïñïáðáëëáãÝò
  9. ÅéóáãùãÞ óðïõäáóôþí ÁÌÅÁ

    Áðü ôï Õðïõñãåßï Ðáéäåßáò êáé ÈñçóêåõìÜôùí áíáêïéíþíåôáé üôé ïé õðïøÞöéïé ðïõ ðÜó÷ïõí áðü óïâáñÝò ðáèÞóåéò (ð.÷. ÐÁÓ×ÏÍÔÅÓ ÁÐÏ ÓÕÍÄÑÏÌÏ ÅÐÉÊÔÇÔÇÓ ÁÍÏÓÏËÏÃÉÊÇÓ ÁÍÅÐÁÑÊÅÉÁÓ (AIDS) ÕÐÏ ÁÍÔÉÑÅÔÑÏÚÊÇ ÈÅÑÁÐÅÉÁ) êáëïýíôáé íá õðïâÜëïõí çëåêôñïíéêÜ, ìÝóù Äéáäéêôýïõ, ìç÷áíïãñáöéêü äåëôßï ìå ôéò ðñïôéìÞóåéò ôìçìÜôùí êáé ó÷ïëþí ðïõ åðéèõìïýí íá åéóá÷èïýí óôçí ÔñéôïâÜèìéá Åêðáßäåõóç ôï áêáä. Ýôïò 2014-2015, óå ðïóïóôü 5% åðéðëÝïí ôùí èÝóåùí åéóáêôÝùí, áðü 15 ìÝ÷ñé êáé 22 Óåðôåìâñßïõ 2014.

    Ç ðëáôöüñìá èá åßíáé ðñïóâÜóéìç óôçí éóôïóåëßäá www.minedu.gov.gr êáé ïé õðïøÞöéïé èá ìðïñïýí íá õðïâÜëïõí ôï ìç÷áíïãñáöéêü ôïõò äåëôßï ìå ôéò ðñïôéìÞóåéò ôùí ó÷ïëþí ðïõ åðéèõìïýí íá åéóá÷èïýí êáé íá äçëþóïõí üëá ôá óôïé÷åßá ðïõ åßíáé áðáñáßôçôá ãéá ôçí õðïøçöéüôçôÜ ôïõò.

    Ç åöáñìïãÞ óõíïäåýåôáé áðü ïäçãßåò, ôéò ïðïßåò ïé õðïøÞöéïé ïöåßëïõí íá ìåëåôÞóïõí ðñïóåêôéêÜ êáé íá áêïëïõèÞóïõí ðéóôÜ ôá ðñïôåéíüìåíá âÞìáôá ãéá ôç óùóôÞ óõìðëÞñùóç ôïõ ìç÷áíïãñáöéêïý äåëôßïõ.

    Ïé õðïøÞöéïé ðñÝðåé íá ãíùñßæïõí üôé áìÝóùò ìåôÜ ôçí çëåêôñïíéêÞ õðïâïëÞ:

    Á. Åêôõðþíïõí áðåõèåßáò áðü ôçí åöáñìïãÞ:

    • Ýíá (1) áíôßãñáöï ôïõ ìç÷áíïãñáöéêïý äåëôßïõ êáèþò êáé
    • ôçí Õðåýèõíç ÄÞëùóç ðïõ åìöáíßæåôáé óôçí «ÁÍÁÓÊÏÐÇÓÇ»
    • óå ðåñßðôùóç õðïâïëÞò ôïõ ìç÷áíïãñáöéêïý äåëôßïõ, áðü íüìéìá åîïõóéïäïôçìÝíï åêðñüóùðï, óõíõðïâÜëëåôáé êáé ç ðñùôüôõðç åîïõóéïäüôçóç.

    Â. ÕðïãñÜöïõí ôá áíùôÝñù Ýããñáöá (ôï ìç÷áíïãñáöéêü äåëôßï óå üëåò ôéò óåëßäåò).

    Ã. ÁðïóôÝëëïõí ôá áíùôÝñù Ýããñáöá ìáæß ìå:

    • Ýíá (1) öùôïáíôßãñáöï ôïõ ôßôëïõ áðüëõóçò
    • Ýíá (1) öùôïáíôßãñáöï ôïõ Ðéóôïðïéçôéêïý äéáðßóôùóçò ôçò ðÜèçóçò, ðïõ Ý÷åé åêäïèåß áðü ôçí áñìüäéá åðôáìåëÞ ÅðéôñïðÞ ôïõ íïóïêïìåßïõ
    • Ýíá (1) öùôïáíôßãñáöï ôçò áóôõíïìéêÞò ôáõôüôçôáò Þ ôïõ äéáâáôçñßïõ

    Ç áðïóôïëÞ èá ðñÝðåé íá ãßíåé Á Ð Ï Ê Ë Å É Ó Ô É Ê Á ÊÁÉ Ì Ï Í Ï ìå ÔÁ×ÕÌÅÔÁÖÏÑÁ (COURIER) ðñïò ôï:

    ÕÐÏÕÑÃÅÉÏ ÐÁÉÄÅÉÁÓ ÊÁÉ ÈÑÇÓÊÅÕÌÁÔÙÍ
    «ÄÉÅÕÈÕÍÓÇ ÏÑÃÁÍÙÓÇÓ ÊÁÉ ÄÉÅÎÁÃÙÃÇÓ ÅÎÅÔÁÓÅÙÍ»
    ÔÌÇÌÁ Á´ ãñ. 0090,
    Á. ÐáðáíäñÝïõ 37, Ô.Ê. 15180, Ìáñïýóé – ÁèÞíá, ÅëëÜäá
    ìå ôçí Ýíäåéîç:
    ãéá ôçí ÅðéôñïðÞ ÓõãêÝíôñùóçò êáé ÅëÝã÷ïõ äéêáéïëïãçôéêþí õðïøçößùí ìå óïâáñÝò ðáèÞóåéò ãéá ôï Ýôïò 2014

    êáé êáôáëçêôéêÞ çìåñïìçíßá ôçò ôá÷õäñïìéêÞò óÞìáíóçò ôçí 23ç Óåðôåìâñßïõ 2014.

    ÌåôÜ ôïí Ýëåã÷ï ôùí óôïé÷åßùí êáé ôçí ôáõôïðïßçóç ìå ôï çëåêôñïíéêü áñ÷åßï, ïé õðïøÞöéïé èá åíçìåñùèïýí ìå íåüôåñç áíáêïßíùóç óôçí éóôïóåëßäá ôïõ Õðïõñãåßïõ ãéá ôçí ïëïêëÞñùóç ôçò äéáäéêáóßáò ôïõ åëÝã÷ïõ êáé ôïí êùäéêü áñéèìü ìå ôïí ïðïßï èá áíáæçôÞóïõí ôá áðïôåëÝóìáôá åéóáãùãÞò óôçí éóôïóåëßäá ôïõ Õðïõñãåßïõ, ìüëéò áíáêïéíùèïýí.

    ÌåôÜ ôçí Ýêäïóç ôùí áðïôåëåóìÜôùí, ïé õðïøÞöéïé êáôáèÝôïõí ïé ßäéïé Þ íüìéìá åîïõóéïäïôçìÝíïò åêðñüóùðüò ôïõò óôç ãñáììáôåßá ôçò ó÷ïëÞò Þ ôìÞìáôïò åðéôõ÷ßáò, ôá ðñùôüôõðá äéêáéïëïãçôéêÜ ðïõ áðáéôïýíôáé, ç ïðïßá êáé èá ðñïâåß óôïí ôåëéêü Ýëåã÷ï ãéá ôçí ðëçñüôçôá êáé ôç íïìéìüôçôÜ ôïõò, ðñïêåéìÝíïõ íá ïëïêëçñùèåß ç åããñáöÞ ôïõò, óôéò çìåñïìçíßåò ðïõ èá ïñéóèïýí. Óå ðåñßðôùóç äéáðßóôùóçò, åßôå êáôÜ ôïí Ýëåã÷ï, åßôå ìåôÜ ôçí åããñáöÞ êáôÜ ïðïéïíäÞðïôå ôñüðï, üôé äåí óõíôñÝ÷ïõí ïé íüìéìåò ðñïûðïèÝóåéò õðáãùãÞò óôçí åéäéêÞ êáôçãïñßá, ëüãù õðïâïëÞò øåõäþí Þ ìç íïìßìùí äéêáéïëïãçôéêþí, ïé åéóá÷èÝíôåò äéáãñÜöïíôáé ìå áðüöáóç ôïõ ôìÞìáôïò Þ ôçò ó÷ïëÞò êáé áðïêëåßïíôáé êáôÜ ôá äýï (2) åðüìåíá áêáäçìáúêÜ Ýôç áðü êÜèå äéáäéêáóßá åéóáãùãÞò óå üëá ôá ôìÞìáôá êáé ôéò ó÷ïëÝò.

    Äéáäéêáóßá ãéá ôçí áðüêôçóç Ðéóôïðïéçôéêïý ÐÜèçóçò

    Ãéá ôçí áðüêôçóç ôïõ Ðéóôïðïéçôéêïý äéáðßóôùóçò ôçò ðÜèçóÞò ôïõò, ïé õðïøÞöéïé ðñÝðåé íá êáôáèÝóïõí ôá áðáñáßôçôá äéêáéïëïãçôéêÜ óå ìßá áðü ôéò åéäéêÝò åðôáìåëåßò ÅðéôñïðÝò ðïõ åäñåýïõí óôá åîÞò Íïóïêïìåßá:
    1. Ðáíåðéóôçìéáêü Ãåíéêü Íïóïêïìåßï (Ð.Ã.Í.) ÁËÅÎÁÍÄÑÏÕÐÏËÇÓ
    2. Ðáíåðéóôçìéáêü Ãåíéêü Íïóïêïìåßï Èåóóáëïíßêçò «Á×ÅÐÁ»
    3. Ãåíéêü Íïóïêïìåßï Èåóóáëïíßêçò «ÐÁÐÁÃÅÙÑÃÉÏÕ»
    4. Ãåíéêü Íïóïêïìåßï Èåóóáëïíßêçò «ÉÐÐÏÊÑÁÔÅÉÏ»
    5. Ðáíåðéóôçìéáêü Ãåíéêü Íïóïêïìåßï ÉÙÁÍÍÉÍÙÍ
    6. Ðáíåðéóôçìéáêü Ãåíéêü Íïóïêïìåßï ËÁÑÉÓÁÓ
    7. Ðáíåðéóôçìéáêü Ãåíéêü Íïóïêïìåßï ÐÁÔÑÙÍ
    8. Ðáíåðéóôçìéáêü Ãåíéêü Íïóïêïìåßï ÇÑÁÊËÅÉÏÕ
    9. Ãåíéêü Íïóïêïìåßï Áèçíþí «Ã. ÃÅÍÍÇÌÁÔÁÓ»
    10. Ãåíéêü Íïóïêïìåßï Áèçíþí «ÊÏÑÃÉÁËÅÍÅÉÏ-ÌÐÅ-ÍÁÊÅÉÏ» Åëëçíéêüò Åñõèñüò Óôáõñüò
    11. Ãåíéêü Íïóïêïìåßï Áèçíþí «ËÁÚÊÏ»
    12. Ãåíéêü Íïóïêïìåßï Áèçíþí «Ï ÅÕÁÃÃÅËÉÓÌÏÓ»
    13. Ãåíéêü Íïóïêïìåßï Íßêáéáò ÐåéñáéÜ «Ï ÁÃÉÏÓ ÐÁÍÔÅËÅÇÌÙÍ»
    14. Ðáíåðéóôçìéáêü Ãåíéêü Íïóïêïìåßï «ÁÔÔÉÊÏÍ»

    ÄéêáéïëïãçôéêÜ ãéá ôçí áðüêôçóç Ðéóôïðïéçôéêïý ÐÜèçóçò

    Ïé õðïøÞöéïé êáôáèÝôïõí áõôïðñïóþðùò Þ ìå íüìéìá åîïõóéïäïôçìÝíï åêðñüóùðï ôïõò Þ ôá÷õäñïìéêþò ìå óõóôçìÝíç åðéóôïëÞ Þ ôá÷õìåôáöïñÜ óå ìßá ìüíï áðü ôéò Åðôáìåëåßò ÅðéôñïðÝò ôùí Íïóïêïìåßùí ôá ðáñáêÜôù äéêáéïëïãçôéêÜ:

    1. Áßôçóç
    2. ÉáôñéêÝò ãíùìáôåýóåéò áðü Äçìüóéï Íïóïêïìåßï ïé ïðïßåò öÝñïõí óöñáãßäá áðü: i) ÓõíôïíéóôÞ ÄéåõèõíôÞ ÊëéíéêÞò Þ Åñãáóôçñßïõ ôïõ Åèíéêïý ÓõóôÞìáôïò Õãåßáò (Å.Ó.Õ.) Þ ii) íüìéìá åêôåëïýíôá ÷ñÝç ÓõíôïíéóôÞ ÄéåõèõíôÞ ÊëéíéêÞò Þ Åñãáóôçñßïõ ôïõ Åèíéêïý ÓõóôÞìáôïò Õãåßáò (Å.Ó.Õ.) Þ iii) ÊáèçãçôÞ Ðáíåðéóôçìßïõ Þ ÁíáðëçñùôÞ ÊáèçãçôÞ êáé
    3. öùôïáíôßãñáöï áóôõíïìéêÞò ôáõôüôçôáò.

    Ãéá ôéò åéäéêÝò åðôáìåëåßò ÅðéôñïðÝò êáé ôéò ðëÞñåéò äéåõèýíóåéò ôïõò ðáôÞóôå åäþ.

    Ãéá ôç ó÷åôéêÞ áßôçóç ðáôÞóôå åäþ.

    Ãéá ôïí ðßíáêá ìå ôéò áóèÝíåéåò êáé ôïõò êùäéêïýò ðáôÞóôå åäþ.

  10. ÁðáëëáãÞ áðü ôç óôñÜôåõóç
  11. ÄùñåÜí áóôéêÝò ôçëåöùíéêÝò êëÞóåéò & Ýêðôùóç Internet


Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò

ÔçëåöùíéêÞ ãñáììÞ ãéá ôï HIV/AIDS

210-7222222

ÄåõôÝñá - ÐáñáóêåõÞ
09:00 - 21:00